Executive Interviews
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
From Mediocre Portfolios to 18% Returns: EFM’s Radical Transparency in Private Markets
Tired of mediocre returns? Emerging Funds Management (EFM) Founding Partner Surendra Pather explains how his firm fills the bank funding gap for developers while delivering 18% returns to sophisticated investors through a radical, transparent fiduciary model.
Silent Pain and Smart Monitors: The High-Stakes Race to De-Risk the Operating Theatre
Anesthesia has long been considered more “art” than science, leaving clinicians to manage high-stakes sedation with aging tools. Cortical Dynamics is changing the clinical reality with BARM 2.0—an AI-powered monitor that provides real-time visibility into the brain’s response to pain and sedation, backed by a global licence and cooperation agreement with Philips and a decade of R&D.
The $3 Billion Blind Spot: How Venstra Medical is using “Collapsible” Physics to Challenge a Global Med-Tech Giant
In the high-stakes theater of the cath lab, cardiogenic shock is the ultimate emergency. Now, a PhD in fluid mechanics and a frontline cardiologist are deploying a “collapsible” breakthrough to disrupt a 30-year monopoly. The Engineer’s Mission For Dr. Martin Cook, the stakes of medical engineering aren’t measured in blueprints, but in heartbeats. A PhD […]
The Blue-Collar ‘Muscle’ Behind Australia’s $100bn Pipeline: One Key Resources Eyes Expansion
As Australia faces a “perfect storm” of low unemployment and an ambitious $100bn project pipeline, One Key Resources MD Ben Lewis explains why the next five years will be defined by the “muscle power” required to deliver the nation’s energy and infrastructure goals.
Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis
Cartherics is bridging the gap in women’s health by utilising iPSC-derived Natural Killer cells to target both ovarian cancer and endometriosis. With a proprietary manufacturing facility and a lead candidate heading to Phase 1 trials, the company is industrialising cell therapy to solve a multi-billion dollar unmet need.
The Billion-Dollar Blind Spot: The Australian Tech Making ‘Invisible’ Decay a Visible Asset for Investors
Incisive Technologies is moving dentistry from “restorative” to “preventative.” By detecting decay at 30 microns—long before it appears on an X-ray—their FDA-approved BlueCheck tool is eliminating the industry’s “watch and wait” mantra and opening a massive new frontier for clinical and at-home oral health monitoring.
Backed By Leading Investment Groups and Family Offices
